SynthesisTechnology in cancer research & treatment

PD-1/PD-L1 Inhibitors Plus Antiangiogenic Drugs Versus Sorafenib as the First Line Treatment for Advanced Hepatocellular Carcinoma: A Phase 3 RCTs Based Meta-Analysis.

Jun Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.